CBIS hit new intraday highs of .088! Could yester
Post# of 63700
Posted On: 07/30/2014 10:58:01 AM
CBIS hit new intraday highs of .088! Could yesterday's federal bill about medical marijuana finally be drawing CBIS the attention it deserves?
Premarket today CBIS put out a press release regarding the bill we have been mentioning all morning:
CBIS Very Excited Over Federal Cannabis
Legalization Efforts in U.S. House and Senate
to Change Medical Cannabis Laws
COLORADO SPRINGS, Colo., July 29, 2014 - Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
U.S. Representative Scott Perry's introduction of a bill, H.R. 5226, yesterday to remove therapeutic, low-THC, high-CBD cannabis oil from the relevant definitions of the federal Controlled Substances Act, thereby permitting treatment throughout the United States of seizure disorders with cannabis, while Cannabis Science has multiple formulations for multiple critical ailments to begin nationwide distribution through its state by state partners and ultimate FDA clinical trials.
These are significant steps towards federal legalization with a widespread impact on the national status of medical cannabis use, which will enable Cannabis Science to move swiftly into a position of great strength to bring its proprietary cannabis formulations to market.
The three other sponsors of the bill include Representatives Dana Rohrabacher (R-CA), Representative Steve Cohen (D-TN), and Representative Paul Broun, MD (R-GA).
The Company also commends U.S. Senator Rand Paul's new announcement to introduce a bill to reschedule cannabis from its Schedule 1 status under the Act and his recent legislative efforts to protect states that have legalized medical cannabis.
"After many successful medical cannabis initiatives on the state level, we are seeing federal lawmakers of both parties actively legislating for medical cannabis reform on a federal level to help patients. Cannabis Science supports these federal efforts and calls on Members of Congress to examine and expand patient-based research and support these critical bills," said Chad S. Johnson, Esq., Director, COO and General Counsel, Cannabis Science, Inc.
Make sure you keep an eye on CBIS!
Premarket today CBIS put out a press release regarding the bill we have been mentioning all morning:
CBIS Very Excited Over Federal Cannabis
Legalization Efforts in U.S. House and Senate
to Change Medical Cannabis Laws
COLORADO SPRINGS, Colo., July 29, 2014 - Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
U.S. Representative Scott Perry's introduction of a bill, H.R. 5226, yesterday to remove therapeutic, low-THC, high-CBD cannabis oil from the relevant definitions of the federal Controlled Substances Act, thereby permitting treatment throughout the United States of seizure disorders with cannabis, while Cannabis Science has multiple formulations for multiple critical ailments to begin nationwide distribution through its state by state partners and ultimate FDA clinical trials.
These are significant steps towards federal legalization with a widespread impact on the national status of medical cannabis use, which will enable Cannabis Science to move swiftly into a position of great strength to bring its proprietary cannabis formulations to market.
The three other sponsors of the bill include Representatives Dana Rohrabacher (R-CA), Representative Steve Cohen (D-TN), and Representative Paul Broun, MD (R-GA).
The Company also commends U.S. Senator Rand Paul's new announcement to introduce a bill to reschedule cannabis from its Schedule 1 status under the Act and his recent legislative efforts to protect states that have legalized medical cannabis.
"After many successful medical cannabis initiatives on the state level, we are seeing federal lawmakers of both parties actively legislating for medical cannabis reform on a federal level to help patients. Cannabis Science supports these federal efforts and calls on Members of Congress to examine and expand patient-based research and support these critical bills," said Chad S. Johnson, Esq., Director, COO and General Counsel, Cannabis Science, Inc.
Make sure you keep an eye on CBIS!
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼